Pharmaceuticals
Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
HEFEI, China, Feb. 25, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory...
2025-02-25 21:00
2052
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces reaching agreements with an investment fund m...
2025-02-25 21:00
2464
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
2559
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
* Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued progression as planned * MRX-4 Injection followed by Contezolid Tablets demonstrated favorable safety and efficacy profiles in patients with...
2025-02-25 18:44
1557
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced the si...
2025-02-25 18:34
1875
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial res...
2025-02-25 18:28
2881
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing investigator-initiated trial (IIT) of YOLT-203 in patients with ...
2025-02-25 16:15
1831
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD) cohort of its randomized, double-blind, placebo...
2025-02-25 14:48
4726
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results supportsugemalimab in combination with chemotherapy as a new standard first-line treatmentfor patients wit...
2025-02-25 12:10
2346
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investi...
2025-02-25 09:13
2066
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines inChina is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announce...
2025-02-25 08:00
2034
3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics
REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of agroundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of...
2025-02-24 23:35
1766
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
* Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resi...
2025-02-24 21:00
1930
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 23, 2025, announced that the company is fully deploying the DeepSeek large model and promoting the application of DeepSeek R1 version across all business ...
2025-02-24 11:20
2349
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2025-02-24 07:56
2753
Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- On February 15, 2025, Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a library capacity of up to 10 trillion, ...
2025-02-23 18:00
2781
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics
2025-02-21 21:15
3067
Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line tr...
2025-02-21 08:47
2462
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
* YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 * First-in-class novel PTH replacement therapy * Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH s...
2025-02-21 00:01
2808
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended31 December 2024. All figures are in AU$ unless stated otherwise. FY2024 highlights * ...
2025-02-20 20:23
3640
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6000
